Novel oral anticoagulants for DC cardioversion procedures: Utilization and clinical outcomes compared with warfarin

PACE - Pacing and Clinical Electrophysiology

Volumn 38, Issue 6, 2015, Pages 731-737

  Coleman, Corey M ^a   Khalaf, Shaden ^a   Mould, Steven ^a   Wazni, Oussama ^a   Kanj, Mohamed ^a   Saliba, Walid ^a   Cantillon, Daniel ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

apixaban; atrial arrhythmias; atrial fibrillation; cardioversion; dabigatran; oral anticoagulation; rivaroxaban; stroke prophylaxis; warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; AGING; ANTICOAGULANT THERAPY; ARTERY EMBOLISM; ARTICLE; BLEEDING; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIRECT CURRENT CARDIOVERSION; DISEASE ASSOCIATION; DRUG UTILIZATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL ARTERIAL EMBOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTOPERATIVE PERIOD; SCORING SYSTEM; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; COMPARATIVE STUDY; HEMORRHAGE; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATIONS; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; DABIGATRAN; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 84930381095     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12618     Document Type: Article

References (18)

1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, et al., 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation 2014; 130: e199-e267.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, et al., Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, et al., Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
5. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, et al., Dabigatran versus warfarin in patients with atrial fibrillation-An analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136.
6. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, et al., Efficacy and safety of apixaban in patients following cardioversion for atrial fibrillation: Insights from the ARISTOTLE trial. J Am Coll Cardiol 2013; 63: 1082-1087.
7. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GH, et al., Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013; 61: 1998-2006.
8. Cappato R, Ezekowitz MD, Klein AL, Camm J, Ma CS, Le Heuzey JY, Talajic M, et al., Rivaroxaban vs. Vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35: 3346-3355.
9. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, et al., Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2011; 344: 1411-1420.
10. Crijins H, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martin A, Pnokowski P, et al., Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. Int J Cardiol 2014; 172: 588-594.
11. Yadlapati A, Groh C, Passman R,. Saftey of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol 2014; 113: 1362-1363.
12. Morris JJ, Kong Y, North WC, McIntosh HD,. Experience with "Cardioversion" of atrial fibrillation and flutter. Am J Cardiol 1964; 14: 94-100.
13. Bjerkelund CJ, Orning OM,. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23: 208-216.
14. Gage BF, Waterman AD, Shannon W, Boecheler M, Rich MW, Radford MJ,. Validation of clinical classification schemes for predicting stroke. JAMA 2001; 285: 2864-2870.
15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM,. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010; 137: 263-272.
16. Lip GY, Gitt AK, Le Heuzey JY, Bash LD, Morabito CJ, Bernhardt AA, Sisk CM, et al., Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol 2014; 113: 480-484.
17. 2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion. Am J Cardiol 2012; 110: 222-226.
18. 2 scoring system to assess left atrial thrombogenic milieu risk before cardioversion of non-valvular atrial fibrillation. Am J Cardiol 2013; 112: 678-683.